9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells

FEBS Lett. 1998 Dec 18;441(2):318-21. doi: 10.1016/s0014-5793(98)01571-3.

Abstract

There is increasing interest in identifying potent inhibitors of telomerase because the enzyme plays a crucial role in the development of cellular immortality and carcinogenesis. We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function. This study was conducted to examine the effect of 9-HE on telomerase activity in human pancreatic cancer cells with differing p53 gene status. 9-HE treatment at relatively high concentrations resulted in rapid, complete inhibition of telomerase activity, irrespective of the p53 status. We conclude that 9-HE may exert a strong inhibitory effect on telomerase activity possibly through inhibition of protein kinases rather than through restoration of functional wild-type p53.

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology*
  • Base Sequence
  • DNA Primers
  • Ellipticines / pharmacology*
  • Enzyme Inhibitors / pharmacology*
  • Genes, p53
  • Humans
  • Pancreatic Neoplasms / enzymology*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / pathology
  • Substrate Specificity
  • Telomerase / antagonists & inhibitors*
  • Telomerase / metabolism
  • Tumor Cells, Cultured

Substances

  • Antimetabolites, Antineoplastic
  • DNA Primers
  • Ellipticines
  • Enzyme Inhibitors
  • 9-hydroxyellipticine
  • Telomerase